32 terminated. 32 Phase 2, 6 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Terminated 32 |
| Phase 3 | 6 | Terminated 6 |
| Phase 1 | 4 | Terminated 4 |
Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JNJ-64281802 for the Prevention of Dengue Infection JNJ-64281802, Placebo - Dengue | Phase 2 | Terminated | Janssen Research & Development, LLC | 1595 | 2023-02-22 | 2025-07-31 |
| A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults R21/Matrix-M, ChAd63/MVA ME-TRAP, intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge - Malaria,Falciparum | Phase 2 | Terminated | University of Oxford | 80 | 2022-08-31 | 2025-02-20 |
| Study of AT-752 in Patients With Dengue Infection AT-752, Placebo - Dengue Fever | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 21 | 2022-04-29 | 2024-03-05 |
| A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever JNJ-64281802, Placebo - Dengue | Phase 2 | Terminated | Janssen Research & Development, LLC | 5 | 2022-01-24 | 2024-03-01 |
| Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease 40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80, Placebo - Chronic Chagas Disease | Phase 2 | Terminated | Juan D. Maya | 300 | 2021-10-12 | 2024-09-19 |
| Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia BBV87 Chikungunya vaccine, Normal Saline - Chikungunya | Phase 2 / Phase 3 | Terminated | International Vaccine Institute | 3210 | 2021-08-01 | 2025-06-22 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria artemether:lumefantrine (2.5 mg:30 mg) - Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2020-12-21 | 2026-01-13 |
| MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria MMV390048 - Malaria | Phase 2 | Terminated | Medicines for Malaria Venture | 8 | 2017-10-20 | 2021-12-09 |
| Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient - Malaria | Phase 2 / Phase 3 | Terminated | London School of Hygiene and Tropical Medicine | 61 | 2015-12-01 | 2016-09-09 |
| A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection DSM265, OZ439 - Malaria | Phase 1 / Phase 2 | Terminated | Medicines for Malaria Venture | 16 | 2015-10-01 | 2020-06-05 |
| Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Eurartesim tablets - Malaria, Vivax | Phase 2 | Terminated | Alfasigma S.p.A. | 27 | 2014-06-18 | 2018-09-17 |
| Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Fexinidazole - Visceral Leishmaniasis | Phase 2 | Terminated | Drugs for Neglected Diseases | 14 | 2013-11-01 | 2015-10-30 |
| Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous Leishmaniasis WR 279,396 - Leishmaniasis, Cutaneous | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 1 | 2013-09-01 | 2019-11-22 |
| WR 279,396 Open Label Treatment Protocol in Tunisia WR 279,396 topical cream - Cutaneous Leishmaniasis | Phase 2 | Terminated | U.S. Army Medical Research and Development Command | 50 | 2011-12-01 | 2014-12-19 |
| Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria SAR97276A, arthemeter + lumefantrine (ACTs) - Malaria | Phase 2 | Terminated | Sanofi | 20 | 2011-10-01 | 2012-12-13 |
| Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria Sevuparin sodium + atovaquone/proquanil, atovaquone/proquanil - Malaria, Falciparum | Phase 1 / Phase 2 | Terminated | Modus Therapeutics AB | 53 | 2011-09-01 | 2014-08-19 |
| Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine p52-/p36- GAP Vaccine, p52-p36- GAP Vaccine - Malaria | Phase 1 / Phase 2 | Terminated | Seattle Children's Hospital | 6 | 2010-03-01 | 2019-10-28 |
| Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) FSME-IMMUN 0.5ml Baxter - Tick-Borne Encephalitis, Encephalitis, Tick-Borne | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 69 | 2009-09-25 | 2018-07-05 |
| Treatment of West Nile Virus With MGAWN1 MGAWN1, Placebo - normal saline - West Nile Neuroinvasive Disease, West Nile Virus Infection | Phase 2 | Terminated | MacroGenics | 13 | 2009-05-01 | 2022-02-10 |
Showing 20 of 32. Sign in to see all of them.
Malaria (9) · Malaria, Falciparum (7) · Leishmaniasis, Cutaneous (5) · Dengue (3) · Leishmaniasis (3) · Leishmaniasis, Visceral (3) · Malaria, Vivax (2) · Chagas Disease (1) · Chikungunya Fever (1) · Encephalitis (1) · Encephalitis, Tick-Borne (1) · Hemorrhagic Fevers, Viral (1) · Infections (1) · Inflammation (1) · Lymphoma, Follicular (1)
Infections (31) · Parasitic Diseases (26) · Protozoan Infections (25) · Mosquito-Borne Diseases (20) · Euglenozoa Infections (10) · Arbovirus Infections (6) · Malaria (6) · RNA Virus Infections (6) · Skin Diseases (6) · Skin Diseases, Infectious (6) · Skin Diseases, Parasitic (6) · Skin and Connective Tissue Diseases (6) · Flaviviridae Infections (5) · Flavivirus Infections (5)
Azithromycin (3) · Chloroquine (3) · Paromomycin (2) · AT-752 (1) · Albendazole (1) · Antimony (1) · Atovaquone (1) · DSM265 (1) · Eflornithine (1) · Injections, Intradermal (1) · Lumefantrine (1) · MMV390048 (1) · Meglumine Antimoniate (1) · Pentoxifylline (1) · Primaquine (1)
U.S. Army Medical Research and Development Command (4) · Drugs for Neglected Diseases (2) · Janssen Research & Development, LLC (2) · Medicines for Malaria Venture (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Pfizer (2) · Sanofi (2) · AB Foundation (1) · AbbVie (1) · Alfasigma S.p.A. (1) · Ana Rabello (1) · Atea Pharmaceuticals, Inc. (1) · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (1) · Epicentre (1) · Foundation Fader (1)
Thailand (5) · Brazil (4) · United States (4) · Burkina Faso (3) · Colombia (3) · Kenya (3) · Benin (2) · Democratic Republic of the Congo (2) · Ethiopia (2) · Gabon (2) · Malaysia (2) · Panama (2) · Peru (2) · Philippines (2) · Sudan (2)
Afif Ben Salah, M.D., Ph.D. (1) · Ahmed M Musa, MD PhD (1) · Ana Rabello, MD PhD (1) · Anna Leitgeb, PhD (1) · Blaise Genton, MD, PhD (1) · Christoph Hatz, Prof Dr Med (1) · E. AG Khalil, Prof. MD (1) · Esayas Gudina, MD (1) · Gerardo Priotto, MD MPH (1)
PMID 28472957, PMID 21375777, PMID 24029408, PMID 24454970, PMID 29121061, PMID 29244851, PMID 29324864, PMID 30269312, PMID 30858218, PMID 32479608, PMID 34179977, PMID 36509063, PMID 36638112, PMID 41199347, PMID 41495411, PMID 42253092